- Home
- ALNY
as 07-26-2024 4:00pm EST
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Upcoming Earnings Alert:
Get ready for potential market movements as Alnylam Pharmaceuticals Inc. ALNY prepares to release earnings report on 01 Aug 2024.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 30.1B | IPO Year: | 2004 |
| Target Price: | $258.05 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $141.98 - $263.73 | Next Earning Date: | 08-01-2024 |
| Revenue: | $2,003,335,000 | Revenue Growth: | 75.20% |
| Revenue Growth (this year): | 4.69% | Revenue Growth (next year): | 21.47% |
Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jul 11 '24 | Sell | $261.00 | 7,093 | $1,851,273.00 | 73,441 | SEC Form 4 |
| SCHULMAN AMY W | ALNY | Director | Jun 25 '24 | Sell | $240.00 | 8,500 | $2,040,000.00 | 8,436 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $235.19 | 863 | $202,968.97 | 80,534 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $234.66 | 957 | $224,569.62 | 81,397 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $233.53 | 595 | $138,950.35 | 82,354 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $232.54 | 1,119 | $260,212.26 | 82,949 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $231.59 | 511 | $118,342.49 | 84,068 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $229.93 | 1,572 | $361,449.96 | 84,579 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $229.06 | 1,374 | $314,728.44 | 86,151 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $228.30 | 666 | $152,047.80 | 87,525 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $226.82 | 177 | $40,147.14 | 88,191 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $225.55 | 93 | $20,976.15 | 88,368 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $224.17 | 66 | $14,795.22 | 88,461 | SEC Form 4 |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Jun 24 '24 | Sell | $221.71 | 308 | $68,286.68 | 88,527 | SEC Form 4 |
| PYOTT DAVID E I | ALNY | Director | Jun 24 '24 | Sell | $220.00 | 17,560 | $3,863,200.00 | 15,026 | SEC Form 4 |
| PYOTT DAVID E I | ALNY | Director | Jun 24 '24 | Sell | $221.00 | 7,420 | $1,639,820.00 | 7,606 | SEC Form 4 |
| PYOTT DAVID E I | ALNY | Director | Jun 24 '24 | Sell | $222.00 | 7,470 | $1,658,340.00 | 136 | SEC Form 4 |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jun 24 '24 | Sell | $221.71 | 78 | $17,293.38 | 17,634 | SEC Form 4 |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jun 24 '24 | Sell | $224.17 | 17 | $3,810.89 | 17,617 | SEC Form 4 |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jun 24 '24 | Sell | $225.55 | 24 | $5,413.20 | 17,593 | SEC Form 4 |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jun 24 '24 | Sell | $226.82 | 45 | $10,206.90 | 17,548 | SEC Form 4 |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jun 24 '24 | Sell | $228.30 | 169 | $38,582.70 | 17,379 | SEC Form 4 |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jun 24 '24 | Sell | $229.06 | 348 | $79,712.88 | 17,031 | SEC Form 4 |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jun 24 '24 | Sell | $229.93 | 398 | $91,512.14 | 16,633 | SEC Form 4 |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Jun 24 '24 | Sell | $231.59 | 129 | $29,875.11 | 16,504 | SEC Form 4 |
Latest Alnylam Pharmaceuticals Inc. News
ALNY Breaking Stock News: Dive into ALNY Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Simply Wall St.
4 days ago
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Business Wire
9 days ago
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
MT Newswires
12 days ago
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing
Simply Wall St.
13 days ago
Alnylam Pharmaceuticals (NASDAQ:ALNY) rallies 3.8% this week, taking five-year gains to 246%
Simply Wall St.
17 days ago
Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value
Clinical Trials Arena
19 days ago
Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win
GuruFocus.com
21 days ago
Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings
Compare ALNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALNY Alnylam Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.